Pre-Characterized CTL Library for HLA-Matched T-Cell Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current systems lack efficient methods for coordinating and delivering allogeneic T-cell therapies, which require matching the T-cell therapy with each patient's immune system, complicating storage and distribution, unlike traditional off-the-shelf therapies.

Innovation Solution

A system comprising a product repository of antigen-specific Cytotoxic T-Lymphocytes (CTLs) with known HLA profiles, a communication channel for patient data, an allogeneic T-cell match generator, and a delivery system that prioritizes and ships matched CTLs to patients based on HLA profiles, ensuring rapid and effective administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If allogeneic T-cell therapies are prepared as off-the-shelf products, then convenience and availability are improved, but coordination with patient immune system characteristics becomes complex

Engineering Contradiction:

Improveconvenience of therapy deliveryVSAvoidcomplexity of coordinating T-cell therapy with patient immune system

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The system performs HLA typing and CTL line selection in advance, before patient treatment is needed. Multiple allogeneic CTL lines are pre-characterized with their HLA profiles and reactivity patterns, allowing rapid matching when a patient requires therapy without time-consuming preparation at the point of care.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent introduces an HLA profile matching system as an intermediary between the off-the-shelf CTL products and patients. By using HLA compatibility as the matching criterion, the system simplifies the coordination process while maintaining immunological compatibility, making off-the-shelf delivery feasible.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If multiple allogeneic CTL lines are stored for patient matching, then treatment options are improved, but storage and distribution logistics become complex

Engineering Contradiction:

Improvetreatment options for different patientsVSAvoidlogistical complexity of storing and distributing multiple CTL lines

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The system segments the allogeneic CTL library into distinct lines, each characterized by specific HLA profiles and reactivity patterns. This segmentation allows the library to be organized and stored in a systematic way, with each CTL line serving as an independent unit that can be matched to patients based on their HLA characteristics.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses HLA profile parameters as the basis for organizing and selecting CTL lines. By characterizing each CTL line with specific HLA parameters and reactivity profiles, the system enables efficient matching and selection from the library without requiring complex real-time analysis, simplifying storage and distribution logistics.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If HLA-matched CTL lines are selected for each patient, then treatment efficacy is improved, but time required for patient screening and matching increases

Engineering Contradiction:

Improvetreatment efficacy through HLA matchingVSAvoidtime for patient screening and CTL line matching

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The system performs the time-consuming HLA typing and CTL line characterization in advance, creating a pre-matched library of allogeneic CTL lines with known HLA profiles and reactivity patterns. When a patient needs treatment, the matching process is rapid because the candidate CTL lines have already been characterized and are ready for comparison with the patient's HLA profile.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20250226072A1Systems and methods for distributing cell therapies

Publication Date: 2025.07.10 ATARA BIOTHERAPEUTICS INC

AI summary

The disclosure relates to delivery systems, and corresponding methods, for selecting and delivering an allogeneic T-cell line for administration to a patient, e.g., according to the HLA profile of the patient's somatic or diseased cells.